Learn what to expect during a supervised Spravato appointment in New York, including FDA requirements, the mandatory two-hour observation period, and clinical safety protocols.
For adults considering alternative psychiatric treatments, understanding the clinical process is a vital first step. Spravato (esketamine) is an FDA-approved nasal spray used in conjunction with an oral antidepressant. It is indicated specifically for adults with Treatment-Resistant Depression (TRD) and adults with Major Depressive Disorder (MDD) experiencing acute suicidal ideation or behavior.
Due to the nature of the medication, Spravato cannot be dispensed at a standard pharmacy for home use. Instead, it is administered in certified healthcare settings under strict observation protocols. This educational overview outlines what a supervised Spravato visit entails in a New York clinic.
The REMS Program and Clinic Certification
Spravato is governed by a Risk Evaluation and Mitigation Strategy (REMS) program designed to mitigate the risks of serious adverse outcomes resulting from sedation, dissociation, and potential abuse or misuse. In New York, any facility administering this treatment—from specialty psychiatric clinics in Manhattan to community health centers in the Hudson Valley—must be REMS-certified.
This certification ensures that the clinic has the necessary monitoring equipment, trained medical personnel, and emergency protocols in place to observe patients safely during and after medication administration.
Arrival and Preparation
A typical Spravato visit begins with a standardized check-in process. Upon arrival at one of the certified locations, clinical staff will review your current health status and any recent changes in your medical history or medications.
Before administration, a healthcare provider will take your baseline vital signs, paying particular attention to your blood pressure. Spravato can cause a temporary increase in blood pressure, so a baseline reading is required to ensure it is within a safe range to proceed. If your blood pressure is elevated, the provider may delay or reschedule the treatment. You will also be shown to a designated treatment room, which is often designed to be quiet and comfortable, with reclining chairs and minimal environmental stimuli.
Administration and the Observation Period
Unlike an IV ketamine infusion, which is administered intravenously, Spravato is a nasal spray. The patient self-administers the medication under the direct, continuous or intermittent supervision of a healthcare provider. The provider instructs you on how to use the device but does not administer the spray for you.
Once the medication is administered, the mandatory observation period begins. The FDA requires patients to be monitored for a minimum of two hours. During this time, clinical staff will periodically check your blood pressure and assess you for common side effects.
Patients may experience varying degrees of dissociation (feeling disconnected from oneself or one's thoughts, feelings, and physical body), sedation, dizziness, nausea, or altered sensory perception. Because these effects typically peak around 40 minutes post-administration and resolve within a few hours, the clinic environment is structured to support resting quietly. Providers may suggest bringing a curated playlist, eyeshades, or comforting items to help manage the sensory experience.
Distinguishing from Compounded Ketamine
It is important to understand the distinction between FDA-approved Spravato and compounded ketamine. The FDA has issued specific warnings to patients and healthcare providers regarding the potential risks associated with compounded ketamine products, including sublingual troches or at-home nasal sprays, which lack the standardized dosing and rigorous safety profiles of approved medications. The supervised clinic environment is specifically mandated for Spravato to manage these inherent risks. Patients can find more clinical background through independent research on FDA guidelines.
Discharge and Post-Treatment Safety
At the end of the two-hour observation period, a healthcare provider will conduct a final assessment to ensure you are clinically stable for discharge. Because the lingering effects of esketamine can impair cognitive and motor function, strict transportation rules apply.
You are not permitted to drive a vehicle, operate machinery, or engage in activities requiring complete mental alertness until the day following the treatment, and only after you have had a restful sleep. A trusted driver or escort must be present to take you home.
Before beginning a treatment regimen, a thorough consultation with a psychiatric provider is required to determine if Spravato is medically appropriate and to outline a specific treatment schedule, which typically involves twice-weekly visits initially, tapering over several weeks. Coverage for these visits varies widely, and patients must individually confirm their benefits with their insurance provider.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.